Last reviewed · How we verify
Phase I dose escalation
At a glance
| Generic name | Phase I dose escalation |
|---|---|
| Sponsor | Suzhou Genhouse Bio Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers (PHASE1)
- A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (PHASE1, PHASE2)
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors (PHASE1)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus (PHASE1)
- HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor (PHASE1, PHASE2)
- The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias (PHASE1, PHASE2)
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |